Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/11/2018 |
| Start Date: | April 18, 2018 |
| End Date: | March 2020 |
| Contact: | Sudhakar Sattur, MD |
| Email: | Sudhakar.Sattur@guthrie.org |
| Phone: | 570-887-6072 |
A Randomized Controlled Trial of Patients Undergoing Percutaneous Coronary Intervention Who Receive Ticagrelor and Fentanyl
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation.
Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study
has demonstrated the decrease in effectiveness of Ticagrelor when administered along with
Fentanyl. Hence this study was designed to further assess the interaction between crushed vs
non crushed Ticagrelor and Fentanyl given during PCI procedures.
Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study
has demonstrated the decrease in effectiveness of Ticagrelor when administered along with
Fentanyl. Hence this study was designed to further assess the interaction between crushed vs
non crushed Ticagrelor and Fentanyl given during PCI procedures.
Inclusion Criteria:
- Undergoing clinically indicated elective or non-elective PCI
- Able to swallow oral medications
Exclusion Criteria:
- Contraindications to ticagrelor or fentanyl (or other opiates)
- Pregnancy
- Any use of P2Y12 inhibitors within 14 days
- Known coagulation disorders
- Pre-procedural treatment with an anticoagulant (oral anticoagulant or low molecular
weight heparin)
- Platelet count < 100,000/mm3
- Impaired renal function (Estimated glomerular filtration < 45 ml/min/1.73 m2)
- Impaired hepatic function (Based on medical history)
- Prior or planned transcatheter aortic valve replacement
We found this trial at
1
site
Sayre, Pennsylvania 18840
Principal Investigator: Sudhakar Sattur, MD
Phone: 570-887-4882
Click here to add this to my saved trials
